BlepharitisBlephaNCT04858113
Short-term Effects on Tear Film (Baby Shampoo vs Blephasol)
A study testing Blephaclean in people with Blepharitis, run by University of Plymouth at 1 site in United Kingdom.
Trial summary
Lid cleansing is the standard regime that is recommended for the management of blepharitis in the UK and beyond. Whilst many successful commercial preparations exist, and some with clinical evidence, professional guidelines (UK Royal College of Ophthalmologists, UK College of Optometrists, AAO, etc.) continue to… Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Blepharitis
- What is being tested?
- Blephaclean
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Oct 2018to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Subjects must be over 18 and under 60 years of age
- Completed a comprehensive eye exam in the last two years
- Contact lens wearers must have stopped wearing for a minimum of two days if wearing soft contact lenses and one week if wearing RGP lenses.
- The subject must have an adequate understanding of the English language to be able to comprehend the oral and written instructions.
Who cannot join
- Determination during enrolment:
- Pregnancy or breast-feeding whilst the examination
- Application of any eye drops within the last 48 hours before the examination
- Application of medication within the last 30 days which influences the body water regulation system (e.g. antidepressants, diuretics, corticosteroids, histamine-receptor antagonist, immune-modulators)
- Change of ocular therapy within the last 30 days before the examination
- Permanent application of eye drops or ocular medication
Show all 14Show fewer
- On-going ocular treatment
- Any kind of ocular pathology or history of refractive surgery
- Any kind of systemic disease which affect collagen and the body water regulation system (Marfan syndrome, osteogenesis imperfect, pseudoxanthoma elasticum, Ehlers-Danlos, diabetes, rosacea, acne, cardiovascular disease, thyroid disease)
- Early termination of the study:
- Drop-out: active termination (decision made by the test person)
- Decision made by the examiner (inadequate compliance, change in the medical condition, as a result, the exclusion criterion is fulfilled)
- Decision made by the lead investigator/ sponsors
- It is possible to withdraw the participation in the study at any time. The participant is not liable to give any reasons for withdrawing. If the study is withdrawn because of the decision of the investigator, the reasons must be given in the screening form.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
University of Plymouth
Plymouth, Devon, PL68AA
Daniela Oehring, PhD, daniela.oehring@plymouth.ac.uk
Daniela Oehring, PhD
About this study
Official title: Pilot Project: Comparing the Short-term Effects on the Tear Film and Lid Margin Between Diluted Baby Shampoo and Blephaclean
Lid cleansing is the standard regime that is recommended for the management of blepharitis in the UK and beyond. Whilst many successful commercial preparations exist, and some with clinical evidence, professional guidelines (UK Royal College of Ophthalmologists, UK College of Optometrists, AAO, etc.) continue to advocate the use of a diluted solution of baby shampoo, despite no clinical evidence of its safety, tolerance or long term effectiveness, and despite a statement form the manufacturers that it should not be used for this purpose. Where licensed, registered products exist it seems bizarre that we have this situation, but a Cochrane review from 2012 indicated that only a longitudinal, randomized controlled trial against baby shampoo would alter their conclusions. Whilst that sort of clinical study is possible, it is proposed here to start with a short-term study to look at the immediate changes induced in the tear film and ocular surface when comparing baby shampoo with Blephasol solution, in a blind, randomized controlled trial.
Read the detailed description
Aims/Key Questions: The hypothesis is: Diluted baby shampoo is more disruptive and deleterious to the human tear film and ocular surface than Blephaclean solution. It is expected that there will be a clinically meaningful difference (approximately 30%) in the non-invasive tear-break up time after the application of baby shampoo compared to Blephaclean.
Potential outcomes: To raise awareness that the safety profile of baby shampoo is insufficient to make it a professional and ethical recommendation for daily lid hygiene.
Recruitment: All subjects will be recruited from the staff and student population of the Faculty of Health and Human Sciences, Plymouth University as well as patients of The Centre for Eyecare Excellence (CEE) and Well-being centre (WBC) at Plymouth University. The recruitment will be carried out via email, flyers and direct invitation. After the first contact, the information sheet, as well as the informed contents, will be sent, or a printed version will be given to all potential subjects.
Design: This prospective study is a two-visit, prospective, cross-sectional, double-blinded and randomized controlled trial. The basic population is described as a healthy UK population with diverse ethnic backgrounds and physiological variation. The principal investigator will carry out the data collection at the Peninsula Allied Health Centre, CEE or WBC (Plymouth University). Ethical approval was grantet. This study conforms to the ethical principles of the Declaration of Helsinki, ICH guidelines for Good Clinical Practice (GCP) and Plymouth University's Principles for Research Involving Human Participants.
Sample size calculations were performed for detecting differences between two dependent not-normally distributed means. A maximum effect size (NIK-BUT difference after the application of baby shampoo compared to Blephaclean) of 0.4 is expected with alpha=0.05 and beta=0.20 (80% power). A sample size of 52 will be required. If considering potential dropouts, the study will aim to recruit 60 subjects. The effect size was calculated based on the distribution of the NIK-BUT in healthy eyes (Abdelfattah et al. 2015).
Primary outcome measure: The non-invasive Keratograph (tear film) break-up time (NIK-BUT) is defined as the primary outcome parameter for the present study. The NIKBUT is defined as the interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film detected automatically by the Keratograph 5M (in seconds).
Randomisation Method: The choice of the eye side, as well as the first cleansing product, will be randomised to minimise investigator bias. Block-wise randomisation is chosen to guarantee an equal group size. The block size is calculated with m = 2n (n means a number of possible groups) per group.
Subject History \& Study Eligibility (Fig. 1 - 1 \& 2): Before determining study eligibility for each subject, the information sheet and the informed content will be handed out to the patient subject again. During recruitment potential subjects will also be given the information sheet. This will ensure that the participant has had sufficient time to understand the study and make an informed decision about participating in the study. Eligible subjects will be allowed to continue. Non-eligible subjects will be dismissed at this time. Subjects will have procedures performed on both eyes. Testing order was designed to sequentially administer the least invasive test to the most invasive test. This methodology will ensure that a previous procedure will have a minimal effect on all subsequent assessments.
Visual Acuity with height and low contrast: The investigator will measure the subject's visual acuity (VA) on a calibrated LogMAR chart at 100% contrast and FrACT for low contrast VA. If the patient is unable to read the 6/12 letters monocular, the investigator will pinhole over the patient's unaided or presenting refractive error correction to determine the subject's visual potential. After finishing both eyes separately, the visual acuity will be examined binocularly with the same procedure.
Questionnaires: Subjects will be asked to complete the OSDI and McMonnies questionnaires.
Tear film \& ocular surface assessment: The tear film will be examined with the Oculus Keratograph 5M from Oculus Optikgeräte GmbH (following K5M). This will include automatic assessments of the Non-Invasive Keratograph Break-Up time (NIKBUT), the tear meniscus height, lipid layer assessment, tear flow and bulbar (conjunctival) redness. Additionally, the K5M will also be used to assess corneal and conjunctiva staining. For assessing bulbar and palpebral conjunctival staining a sterile Lissamine green strip will be wet with sterile saline and applied to the superior bulbar conjunctiva.
Lid cleansing procedure: One investigator will prepare the products such that the principal investigator and the participant are masked. The Principal investigator will apply the product to the upper and lower lid areas and margins, using standard techniques. One eye will be treated using Blephaclean the other eye will be treated using baby shampoo, randomised for visit 1 and visit 2. The Principal investigator needs to apply and gently massage foam from one bottle onto the periocular skin of the closed superior and inferior eyelids of the designated eye with clean fingertips for one minute before rinsing with water, and to take care to avoid the transfer of residual products to the fellow eye during cleansing and drying. The Principal investigator has to avoid direct contact with the ocular surface, and to clean their hands prior to using the second treatment for the fellow eye, in order to prevent cross contamination.
- Conditions
- Blepharitis
- Being tested
- Blephaclean, Baby Shampoo
- Medical subject headings
- Blepharitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BlephacleanOther
Blephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction.
Baby ShampooOther
Conventional baby shampoo
| Study group | Role | What they receive |
|---|---|---|
| Baby Shampoo | Placebo comparator | Conventional Baby shampoo Receives: Other: Baby Shampoo |
| No intervention | No intervention | Baseline condition without intervention |
| Blephaclean | Experimental | Intervention Receives: Other: Blephaclean |
What is being measured
The primary outcome is the main question the study is designed to answer.
NIKBUT
Non-invasive break up time
Measured: 1 day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2021
- Study start1 Oct 2018
- Primary completion1 Oct 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BlepharitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Plymouth
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Daniela Oehring, University of Plymouth
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04858113
- Sponsor's protocol ID
- SoHP_DO_05
- Acronym
- Blepha
- Status last verified
- Nov 2022
- First submitted
- 19 Apr 2021
- Last updated
- 9 Nov 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Project: Comparing the Short-term Effects on the Tear Film and Lid Margin Between Diluted Baby Shampoo and Blephaclean
- ClinicalTrials.gov ID
- NCT04858113
- Acronym / sponsor ID
- Blepha / SoHP_DO_05
- Conditions
- Blepharitis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of PlymouthUniversity, hospital or other
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 1 Oct 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 26 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Lid cleansing is the standard regime that is recommended for the management of blepharitis in the UK and beyond. Whilst many successful commercial preparations exist, and some with clinical evidence, professional guidelines (UK Royal College of Ophthalmologists, UK College of Optometrists, AAO, etc.) continue to advocate the use of a diluted solution of baby shampoo, despite no clinical evidence of its safety, tolerance or long term effectiveness, and despite a statement form the manufacturers that it should not be used for this purpose. Where licensed, registered products exist it seems bizarre that we have this situation, but a Cochrane review from 2012 indicated that only a longitudinal, randomized controlled trial against baby shampoo would alter their conclusions. Whilst that sort of clinical study is possible, it is proposed here to start with a short-term study to look at the immediate changes induced in the tear film and ocular surface when comparing baby shampoo with Blephasol solution, in a blind, randomized controlled trial.
Detailed description
Aims/Key Questions: The hypothesis is: Diluted baby shampoo is more disruptive and deleterious to the human tear film and ocular surface than Blephaclean solution. It is expected that there will be a clinically meaningful difference (approximately 30%) in the non-invasive tear-break up time after the application of baby shampoo compared to Blephaclean.
Potential outcomes: To raise awareness that the safety profile of baby shampoo is insufficient to make it a professional and ethical recommendation for daily lid hygiene.
Recruitment: All subjects will be recruited from the staff and student population of the Faculty of Health and Human Sciences, Plymouth University as well as patients of The Centre for Eyecare Excellence (CEE) and Well-being centre (WBC) at Plymouth University. The recruitment will be carried out via email, flyers and direct invitation. After the first contact, the information sheet, as well as the informed contents, will be sent, or a printed version will be given to all potential subjects.
Design: This prospective study is a two-visit, prospective, cross-sectional, double-blinded and randomized controlled trial. The basic population is described as a healthy UK population with diverse ethnic backgrounds and physiological variation. The principal investigator will carry out the data collection at the Peninsula Allied Health Centre, CEE or WBC (Plymouth University). Ethical approval was grantet. This study conforms to the ethical principles of the Declaration of Helsinki, ICH guidelines for Good Clinical Practice (GCP) and Plymouth University's Principles for Research Involving Human Participants.
Sample size calculations were performed for detecting differences between two dependent not-normally distributed means. A maximum effect size (NIK-BUT difference after the application of baby shampoo compared to Blephaclean) of 0.4 is expected with alpha=0.05 and beta=0.20 (80% power). A sample size of 52 will be required. If considering potential dropouts, the study will aim to recruit 60 subjects. The effect size was calculated based on the distribution of the NIK-BUT in healthy eyes (Abdelfattah et al. 2015).
Primary outcome measure: The non-invasive Keratograph (tear film) break-up time (NIK-BUT) is defined as the primary outcome parameter for the present study. The NIKBUT is defined as the interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film detected automatically by the Keratograph 5M (in seconds).
Randomisation Method: The choice of the eye side, as well as the first cleansing product, will be randomised to minimise investigator bias. Block-wise randomisation is chosen to guarantee an equal group size. The block size is calculated with m = 2n (n means a number of possible groups) per group.
Subject History \& Study Eligibility (Fig. 1 - 1 \& 2): Before determining study eligibility for each subject, the information sheet and the informed content will be handed out to the patient subject again. During recruitment potential subjects will also be given the information sheet. This will ensure that the participant has had sufficient time to understand the study and make an informed decision about participating in the study. Eligible subjects will be allowed to continue. Non-eligible subjects will be dismissed at this time. Subjects will have procedures performed on both eyes. Testing order was designed to sequentially administer the least invasive test to the most invasive test. This methodology will ensure that a previous procedure will have a minimal effect on all subsequent assessments.
Visual Acuity with height and low contrast: The investigator will measure the subject's visual acuity (VA) on a calibrated LogMAR chart at 100% contrast and FrACT for low contrast VA. If the patient is unable to read the 6/12 letters monocular, the investigator will pinhole over the patient's unaided or presenting refractive error correction to determine the subject's visual potential. After finishing both eyes separately, the visual acuity will be examined binocularly with the same procedure.
Questionnaires: Subjects will be asked to complete the OSDI and McMonnies questionnaires.
Tear film \& ocular surface assessment: The tear film will be examined with the Oculus Keratograph 5M from Oculus Optikgeräte GmbH (following K5M). This will include automatic assessments of the Non-Invasive Keratograph Break-Up time (NIKBUT), the tear meniscus height, lipid layer assessment, tear flow and bulbar (conjunctival) redness. Additionally, the K5M will also be used to assess corneal and conjunctiva staining. For assessing bulbar and palpebral conjunctival staining a sterile Lissamine green strip will be wet with sterile saline and applied to the superior bulbar conjunctiva.
Lid cleansing procedure: One investigator will prepare the products such that the principal investigator and the participant are masked. The Principal investigator will apply the product to the upper and lower lid areas and margins, using standard techniques. One eye will be treated using Blephaclean the other eye will be treated using baby shampoo, randomised for visit 1 and visit 2. The Principal investigator needs to apply and gently massage foam from one bottle onto the periocular skin of the closed superior and inferior eyelids of the designated eye with clean fingertips for one minute before rinsing with water, and to take care to avoid the transfer of residual products to the fellow eye during cleansing and drying. The Principal investigator has to avoid direct contact with the ocular surface, and to clean their hands prior to using the second treatment for the fellow eye, in order to prevent cross contamination.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Baby Shampoo | Placebo comparator | Other: Baby ShampooConventional Baby shampoo |
| No intervention | No intervention | –Baseline condition without intervention |
| Blephaclean | Experimental | Other: BlephacleanIntervention |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Subjects must be over 18 and under 60 years of age
- Completed a comprehensive eye exam in the last two years
- Contact lens wearers must have stopped wearing for a minimum of two days if wearing soft contact lenses and one week if wearing RGP lenses.
- The subject must have an adequate understanding of the English language to be able to comprehend the oral and written instructions.
Key exclusion criteria (14 listed)
- Pregnancy or breast-feeding whilst the examination
- Application of any eye drops within the last 48 hours before the examination
- Application of medication within the last 30 days which influences the body water regulation system (e.g. antidepressants, diuretics, corticosteroids, histamine-receptor antagonist, immune-modulators)
- Change of ocular therapy within the last 30 days before the examination
- Permanent application of eye drops or ocular medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BlephacleanBlephaclean wipes are used to help treat symptoms of blepharitis (eyelid inflammation) which is commonly associated with dry eye disease and meibomian gland dysfunction. | Other | Blephaclean |
| Baby ShampooConventional baby shampoo | Other | Baby Shampoo |
Primary outcome
NIKBUT
Time frame: 1 day
Non-invasive break up time
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2022.
- Individual participant dataSharing planned: No
Related trials for Blepharitis
Not yet recruitingPhase 2
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
Blepharitis
RecruitingObservational study
Ocular Dysbiosis in Eyelid Disease
Anterior Blepharitis
Not yet recruitingPhase 4
Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study
Anterior Blepharitis
RecruitingObservational study
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
Artifical Intelligence, Cataract
RecruitingPhase 2
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Demodex Blepharitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blephaclean in people with Blepharitis, run by University of Plymouth at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daniela Oehring, PhD (+44 (0) 1752 587 547, daniela.oehring@plymouth.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NIKBUT (time frame: 1 day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2022.